| Name | Title | Contact Details |
|---|---|---|
Jackie Gretzinger |
Regional Sales Director | Epicutis | Profile |
SOPHiA GENETICS combines deep expertise in life sciences and medical disciplines with mathematical capabilities in data computing. Our mission is to bring data analytics solutions to market, to support healthcare professionals by maximizing the power of Data-Driven Medicine. We achieve this mission through the global adoption of SOPHiA AI, which is built using techniques such as statistical inference, pattern recognition and machine learning. This enables SOPHiA to provide equal benefits to all users, unite experts in a gold standard health tech platform, and motivate expert knowledge sharing for a sustainable impact on future patients. We want to contribute to make the global healthcare system more sustainable. It is our strong belief that digital technologies are the key to unlocking the era of Data-Driven Medicine, where secure data pooling and knowledge sharing will be extremely valuable for patients. By helping healthcare professionals leverage their expertise and work together as a community, patients all over the world can receive equal access to better diagnoses and treatments. Combining the first two pillars of Data-Driven Medicine, Genomics and Radiomics, we can ensure that the data used to help patients today will also benefit the patients of tomorrow.
DFM is a Morristown, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
BioDuro-Sundia provide its biopharma customers a single end-to-end solution from early stage drug discovery to late stage manufacturing.
Affymax, Inc. is a biopharmaceutical company developing peptide-based drugs to improve the treatment of serious and often life-threatening conditions. The Company's product candidate, Hematide, is designed to treat anemia associated with chronic renal
Vivace Therapeutics is a venture-backed, oncology-focused portfolio-based drug discovery and development company, based in San Mateo, California. Its programs include both small molecule programs targeting the YAP pathway, and bi-specific programs.